Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial
Martin Kaiser(Royal Marsden NHS Foundation Trust), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Richard S. Houlston(Institute of Cancer Research), Kristian M. Bowles(University of East Anglia), Mamta Garg(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Andrew Hall(University of Leeds), Gordon Cook(University of Leeds), Christina Messiou(Institute of Cancer Research), Mark T. Drayson(Institute of Immunology), Ruth M. de Tute(St James's University Hospital), Anand Lokare(University Hospitals Coventry and Warwickshire NHS Trust), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Sarah Brown(University of Leeds), Emma Ingleson(University of Leeds), Sadie Roberts(University of Leeds), Graham Jackson(Newcastle College), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Isabelle L Smith(University of Leeds)
Cited by 10
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Genome-wide association study identifies five susceptibility loci for glioma
|Nature Genetics|2009|797
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605